The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.
 
Sandip Pravin Patel
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Compugen; Lilly; Nektar; Novartis
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Pfizer (Inst); Roche/Genentech (Inst); Xcovery (Inst)
 
Megan Othus
No Relationships to Disclose
 
Young Kwang Chae
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Counsyl; Foundation Medicine; Guardant Health; Hanmi; Immuneoncia; Roche/Genentech; Takeda
Speakers' Bureau - AstraZeneca; Genentech/Roche; Lilly; Merck
Research Funding - Abbvie; Biodesix; Bristol-Myers Squibb; Freenome; Lexent Bio
Travel, Accommodations, Expenses - Hanmi
 
Frank Giles
Stock and Other Ownership Interests - Actuate Therapeutics; Epigene Therapeutics
Consulting or Advisory Role - Actuate Therapeutics; Epigene Therapeutics
 
Jourdain Hayward
No Relationships to Disclose
 
Christine McLeod
No Relationships to Disclose
 
Helen X. Chen
No Relationships to Disclose
 
Elad Sharon
No Relationships to Disclose
 
Edward Mayerson
No Relationships to Disclose
 
Christopher W. Ryan
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer
Research Funding - Argos Therapeutics (Inst); Bristol-Myers Squibb (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline/Novartis (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); MabVax (Inst); Merck (Inst); Morphotek (Inst); Pfizer (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
 
Melissa Plets
No Relationships to Disclose
 
Charles David Blanke
No Relationships to Disclose
 
Razelle Kurzrock
Leadership - CureMatch
Stock and Other Ownership Interests - CureMatch; IDbyDNA; Soluventis
Consulting or Advisory Role - Actuate Therapeutics; Gaido; Loxo; NeoMed; Roche; Soluventis; XBiotech
Speakers' Bureau - Roche
Research Funding - Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst)